

## **Quantitative Measurements of Enlarged Perivascular Spaces in the Brain are Associated with Retinal Microvascular Parameters in Older Community-Dwelling Subjects.**

### **Authors:**

Lucia Ballerini<sup>1,2,3</sup>, PhD; Sarah McGrory<sup>1,3</sup>, PhD; Maria del C. Valdés Hernández<sup>1,2,3</sup> PhD; Ruggiero Lovreglio<sup>4</sup>, PhD; Enrico Pellegrini<sup>1</sup>, PhD; Tom MacGillivray<sup>1,2</sup>, PhD; Susana Muñoz Maniega<sup>1,2,3</sup>, PhD; Ross Henderson<sup>3</sup>, Adele Taylor<sup>6</sup>, Mark E. Bastin<sup>1</sup>, DPhil; Emanuele Trucco<sup>5</sup>, PhD; Ian J. Deary<sup>3,6</sup>, PhD; Joanna Wardlaw<sup>1,2,3</sup>, MD

### **Author Affiliations:**

<sup>1</sup>Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, and VAMPIRE project, University of Edinburgh, Edinburgh, UK

<sup>2</sup>Dementia Research Institute, University of Edinburgh, Edinburgh, UK

<sup>3</sup>Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK

<sup>4</sup>School of Built Environment, Massey University, Auckland, New Zealand

<sup>5</sup>VAMPIRE project, Computing (SSEN), University of Dundee, Dundee, UK

<sup>6</sup>Department of Psychology, University of Edinburgh, Edinburgh, UK

**Word count:** abstract: 298, total words: 6634; Refs: 49, Figures: 5, Tables: 2

**Correspondence:** Joanna Wardlaw, Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, 49 Little France Crescent, Chancellor's Building FU 427, Edinburgh EH16 4SB, UK. e-mail: [joanna.wardlaw@ed.ac.uk](mailto:joanna.wardlaw@ed.ac.uk)

**Running head:** perivascular spaces and retinal vascular measures

**Keywords:** MRI, ageing, perivascular spaces, retina

**Conflicts of interest:** none

## ABSTRACT

**Background:** The retinal and cerebral microvasculature share many morphological and physiological properties. Perivascular Spaces (PVS), also known as Virchow-Robin spaces, are visible with increasing resolution with the ongoing improvement of brain MRI technology. We investigated the associations between quantitative retinal measurements and novel computational PVS parameters in a cohort of older people in their eighth decade.

**Methods:** We analysed data from community-dwelling individuals (n=381 of 866) from the Lothian Birth Cohort 1936, who underwent multimodal brain MRI and retinal fundus camera imaging at mean age 72.55 years (SD=0.71). We assessed PVS computationally in the centrum semiovale. We calculated the total volume and count of PVS, and the mean per-subject individual PVS length, width and size. Digital retinal images were analysed using the VAMPIRE software suite, obtaining the Central Retinal Artery and Vein Equivalent (CRVE and CRAE), Arteriole-to-Venule ratio (AVR), and fractal dimension (FD) of both eyes. We investigated the associations between computational PVS measurements and retinal vascular measurements using general linear models. We adjusted for age, gender and important covariates (hypertension, diabetes, cholesterol, cardiovascular disease history and smoking).

**Results:** In 381 subjects with all measures, increasing total volume and count of PVS were associated with decreased CRAE in the left eye (volume  $\beta=-0.170$   $p<0.001$ ; count  $\beta=-0.184$ ,  $p<0.001$ ). No associations of PVS with CRVE were found. The PVS total volume, individual width and size were associated with the FD of the arterioles (a) and venules (v) of the left eye (total volume: FDa  $\beta=-0.137$ , FDv  $\beta=-0.139$ , both  $p<0.01$ ; width: FDa  $\beta=-0.144$ , FDv  $\beta=-0.158$ , both  $p<0.01$ ; size: FDa  $\beta=-0.157$ ,  $p=0.002$ ; FDv  $\beta=-0.162$ ,  $p=0.001$ ).

**Conclusions:** We show that worse brain PVS computational metrics associate with narrower retinal arterioles and lower retinal microvessel branching complexity, providing more direct evidence in vivo in humans of the microvessel changes underlying brain small vessel disease.

## 1. INTRODUCTION

Due to the developmental, anatomical and physiological similarities of the cerebral and retinal vessels, and the ease with which the retinal microvasculature can be imaged *in vivo*, there has been considerable interest in determining whether pathologic changes in the retinal vessels parallel changes in cerebral vascular health, in particular in small vessel disease (SVD).

Morphological features of the retinal vasculature are associated with stroke, especially small vessel disease (lacunar) stroke<sup>1-4</sup>. Arteriolar branching coefficients of retinal vessels have also been associated with periventricular and deep white matter hyperintensities (WMH)<sup>5</sup>. Reduced fractal dimension (a measure of the complexity of the retinal vascular network) in older people has been related to WMH load and total small vessel disease (SVD) burden<sup>6</sup> and narrower retinal arteriolar calibre to more visible perivascular spaces (PVS) on brain magnetic resonance imaging (MRI)<sup>7</sup>. Retinopathy has been associated with dementia as well, although associations with retinal vascular features are less clear<sup>8</sup>.

Visible PVS, known also as Virchow-Robin spaces, are seen with increasing clarity in brain MRI in older subjects, in SVD, and other neurological disorders<sup>9</sup>. PVS are fluid-filled compartments surrounding small perforating brain microvessels (usually arterioles). They are thought to act as conduits for fluid transport, exchange between cerebrospinal fluid (CSF) and interstitial fluid (ISF) and clearance of waste products from the brain<sup>10</sup>. PVS are visible on T2w and T1w MRI when enlarged as thin linear or punctate structures (depending on scan orientation), oriented with perforating vessels, of similar signal to CSF<sup>11, 12</sup>, having a diameter smaller than 3mm<sup>13, 14</sup>. PVS numbers have been reported to increase with age, with other brain SVD features<sup>13</sup>, as well as with vascular risk factors, especially hypertension, in common brain disorders including stroke, mild cognitive impairment, and dementia including of vascular subtype<sup>9, 15</sup>.

To date, the quantification of enlarged PVS visible in MRI scans has mainly relied on qualitative ordinal visual scores<sup>16</sup>. Whilst shown to provide valuable information about PVS in aetiological studies to date, these scales are inherently insensitive to small details due to their limited number of categories, floor and ceiling effects, and may be affected by observer bias<sup>16</sup>. Computational tools for PVS quantification have been developed in the last five years<sup>17-20</sup>. The method by Ballerini *et al.*<sup>20, 21</sup> was able to segment PVS in the centrum semiovale and enabled quantification of several PVS features, including the total count and total volume per individual subject's brain, plus the size, length, width, shape and direction of each individual PVS. All these can then be analysed as mean or median per individual subject<sup>20</sup> or indeed per brain region. Previously, we showed good agreement between PVS visual rating and computational measures<sup>20, 21</sup>. We also showed associations between PVS individual widths and volume and WMH, which could indicate stagnation (manuscript under review).

Here we investigated the associations between computational PVS measurements and retinal vascular

measurements to determine if changes in PVS morphology such as increased size or number were related to changes in retinal arteriolar or venular morphologies as a surrogate for altered intracranial microvessel morphologies.

## 2. MATERIALS AND METHODS

We used data from a subsample of the Lothian Birth Cohort 1936 (LBC1936)<sup>22</sup>, a community-dwelling cohort being studied in the eighth decade of life. The LBC1936 comprises 1091 individuals survivors of the Scottish Mental Health Survey of 1947, who were recruited into the study at the age of 69. Of these, 866 were tested at the second wave of recruitment, at mean age 72.55 years (SD 0.71), of whom 700 had structural MRI scans, and 814 had retinal scans of both eyes. Analyses were based on subjects with retinal and MRI data that could be processed successfully.

All participants gave written informed consent under protocols approved by the Lothian (REC 07/MRE00/58) and Scottish Multicentre (MREC/01/0/56) Research Ethics Committees (<http://www.lothianbirthcohort.ed.ac.uk/>).

All clinical and imaging acquisition methods and the visual and computational assessment of WMH and PVS visual scores in this cohort have been reported previously<sup>22-24</sup>. Briefly, medical history variables (hypertension, diabetes, hypercholesterolemia, cardiovascular disease history (CVD), smoking and stroke) were assessed at the same age as brain imaging. A history of CVD included ischaemic heart disease, heart failure, valvular heart disease and atrial fibrillation. Stroke data included clinically diagnosed stroke and also those with any ischaemic or haemorrhagic stroke seen in MRI scans in subjects with no clinical history of stroke. All medical history variables were coded as binary variables, indicating presence (1) or absence (0).

Structural brain MRI data were acquired using a 1.5-Tesla GE Signa Horizon HDx scanner (General Electric, Milwaukee, WI), with coronal T1-weighted (T1w), and axial T2-weighted (T2w), T2\*-weighted (T2\*w) and fluid-attenuated inversion recovery (FLAIR)-weighted whole-brain imaging sequences; details in<sup>23</sup>.

Intracranial Volume (ICV) and WMH volume were measured on T2w, T1w, T1\*w and FLAIR scans using a validated semi-automatic pipeline published in full previously<sup>25</sup>. For this study we express WMH as percentage of ICV.

The computational assessment of PVS used the T2w images acquired with 11,320ms repetition time, 104.9ms echo time, 20.83 KHz bandwidth, 2mm slice thickness, and 256 x 256mm field-of-view. The images were reconstructed to a 256 x 256 x 80 matrix, 1mm in-plane resolution. PVS were segmented

in the centrum semiovale with the method described in <sup>20</sup>. This method uses the three-dimensional Frangi filter <sup>26</sup> to enhance and capture the 3D geometrical shape of PVS. It then calculates the PVS count and volume using connected component analysis <sup>27</sup>. The PVS count was defined as the number of connected-component objects in the segmented images. The PVS total volume was the total number of voxels classified as PVS. Individual PVS features (size, length, width) were also measured using connected component analysis. 'PVS size' was defined as the volume of each individual PVS to avoid confusion with 'PVS volume' which was the total volume of all the PVS in an individual subject. PVS length and width were defined, respectively, as the length of the longest and second-longest elongation axes of the ellipsoid approximating the PVS (see Figure 2b). Mean, median, standard deviation and percentiles of length, width and size were calculated for each subject. Before statistical analysis, the segmented PVS binary masks, superimposed on the T2W images, were visually checked by a trained operator (LB), and accepted or rejected blind to all other data. Images were deemed acceptable if the computational method was able to detect a reasonable amount of visible PVS, and did not detect too many artefacts as PVS. A small amount (< 20%) of false positives and negatives was considered acceptable. An example of PVS segmentation is shown in Figure 1.

[INSERT FIGURE 1 ABOUT HERE]

Digital retinal fundus images were captured using a non-mydratic camera at 45° field of view (CRDGi; Canon USA, Lake Success, New York, USA). All images were centred on the optic disc<sup>28</sup>. Retinal vascular measurements were computed for both eyes of each of the 601 included participants using the semi-automated software package, VAMPIRE (Vessel Assessment and Measurement Platform for Images of the REtina) version 3.1<sup>29, 30</sup>, by a trained operator blind to all other data (see the software interface in Figure 2). Quality assessment was performed by a trained operator. The reasons for image rejection included poor image quality, known pathologies or only one eye suitable for measurements. VAMPIRE 3.1 computes 151 morphometric measurements of the retinal vasculature, of which 5 were selected for this study: central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and arteriole-to-venule ratio (AVR), arteriolar and venular fractal dimension (FDa, FDv). CRAE, CRVE and AVR<sup>31-33</sup> were included as standard features summarizing the widths of major vessels near the optic disc. Based on recent findings on the associations between retinal features and brain imaging markers of SVD on this cohort<sup>6</sup>, we also used FD.

[INSERT FIGURE 2 ABOUT HERE]

We used all subjects with suitable PVS and retinal data from both eyes. Following recommendations from previous studies and considering that symmetry of any retinal or ocular structure, or the brain and major vessels to which it is connected, cannot be assumed<sup>34</sup>, we analysed associations with each eye separately.

First, we compared the proportion of the sample for which all computational measures were available to those who were excluded using Welch two sample *t*-tests and chi-squared tests. Next we generated the descriptive statistics for all the variables involved in the analysis and calculated the bootstrapped bivariate cross-correlations between the retinal and brain variables, and controlled for false discovery rate (FDR). Finally, we estimated a series of generalized linear models to detect the associations between retinal vascular measures and PVS metrics. We adjusted for age, gender and vascular risk factors (hypertension, hypercholesterolemia, diabetes, cardiovascular disease, stroke and smoking).

### 3. RESULTS

PVS parameters were computed successfully in 540 out of 700 MRI images (77%). MRI scans that could not be processed successfully mainly contained motion artefacts that appeared as parallel lines similar to PVS. Fundus images of both eyes were available for 814 patients. Retinal measurements were computed successfully in both eyes for 601 out of 814 (74%) subjects. A total of 381 participants had both retinal and PVS measurements suitable for this study. Figure 2 shows a flowchart visualizing of the selection of our analytic sample.

[INSERT FIGURE 3 ABOUT HERE]

Participants excluded from the retina-PVS analysis, due to missing either PVS or retinal data, did not differ from those included as to the proportion by gender, with diabetes, CVD and smokers. However, the group with successful computational PVS and retinal assessment were younger by an average of 44 days (included = 72.47 years, excluded = 72.60,  $p < 0.01$ ). The groups also differed in the proportion of patients with hypertension (included 43.31%, excluded 53.61%) and hypercholesterolaemia (included 34.91%, excluded 45.98%) indicating that the participants who were older, with more co-morbidities and therefore likely frailer were less likely to generate imaging that could be analysed computationally.

The descriptive statistics of the data are given in Table 1. Of the 381 participants at mean age 72.47 (SD 0.69), 186 (48.82%) were female, 165 (43.31%) had hypertension, 34 (8.92%) had diabetes, 133 (34.91%) were hypercholesterolaemic, 100 (26.25%) had CVD, 29 (7.61%) were smokers, and 66 (17.32%) had prior clinical or imaging evidence of stroke. The mean number of PVS in the centrum semiovale was 254.4 (SD 90.13). These correspond with median PVS visual ratings of 2, range 1-4 (Figure 4)<sup>16</sup>. The mean percentage of WMH in the ICV was 0.81 (SD 0.89).

[INSERT TABLE 1 ABOUT HERE]

[INSERT FIGURE 4 ABOUT HERE]

The cross-correlation matrix showing the bivariate associations among brain variables (PVS total volume, count, length, width, size) and retinal vascular measurements (CRAE, CRVE, AVR, FDa, FDv) is shown in Table 2. The PVS total volume and count were negatively correlated with left CRAE and AVR (Figure 5). No significant association was found between venular width and PVS. The total volume of PVS and the individual PVS size and width were negatively correlated with the arteriolar FD of the left eye. These results survived FDR correction. The direction of effect was similar for the right eye but did not reach significance (all  $p > 0.01$ ). In Table 2 can also be observed that the PVS measurements are all strongly associated. The correlations of retinal measures of the left-right eye are not high.

[INSERT TABLE 2 ABOUT HERE]

[INSERT FIGURE 5 ABOUT HERE]

We also tested for significant bivariate associations using general linear models (Table 3). After full covariate adjustment, the total volume and count of PVS were independently negatively associated with left CRAE (volume  $\beta = -0.170$ ,  $p = 0.001$ ; count  $\beta = -0.184$ ,  $p < 0.001$ ). The association between the number of PVS with AVR attenuated to non-significance after adjustments. After correcting for covariates, the PVS total volume was associated negatively with the FD of the arterial and venular vasculature of the left eye (FDa  $\beta = -0.137$ , FDv  $\beta = -0.139$ , both  $p < 0.01$ ). Individual PVS width and size were both associated negatively with FD of the retinal arterioles and venules (width: FDa  $\beta = -0.144$ , FDv  $\beta = -0.158$ , both  $p < 0.01$ ; size: FDa  $\beta = -0.157$ ,  $p = 0.002$ ; FDv  $\beta = -0.162$ ,  $p = 0.001$ ). Smoking was also associated with increased individual PVS width and size ( $\beta$  range = 139 to 160, all  $p < 0.005$ ). These associations survived FDR correction.

[INSERT TABLE 3 ABOUT HERE]

#### 4 DISCUSSION

We found that increase in PVS size, number, width are associated with narrower retinal arterioles, suggesting that perivascular enlargement reflects microvessels changes that are in keeping with microangiopathy. We found that an increasing number of abnormal PVS was associated with decreased arteriolar and venular fractal dimension, indicating reduced branching complexity, independent of covariates.

To our knowledge, this is the first study to evaluate associations of multiple computational measures of PVS enlargement with retinal vascular measurements. Only one previous study reported associations between retinal vessel width and PVS using visual rating scales<sup>7</sup>. The previous study<sup>7</sup> found that narrower arteriolar calibre, and to a lesser extent wider venular calibre, were significantly associated with higher numbers of PVS. The authors hypothesized that a failure in the CSF transmission may result in



hemodynamic pressure differences that might manifest in changes in vascular calibre. They also hypothesized that narrower arterioles may lead to hypoperfusion, resulting in atrophy, and thus to PVS enlargement. Our negative associations between computational PVS metrics and arteriolar calibres are in the same direction. However, we did not find significant associations with venular calibres. Our findings support the hypothesis that increasing PVS total volume, count and individual size are a marker primarily of arteriolar pathology in the brain. There is some suggestion of venular disease in ageing, SVD and dementia<sup>35</sup>. However, our results do not support an association of PVS and venular pathology.

A previous study, using this same cohort<sup>6</sup> also reported associations between fractal dimension and SVD features, although mainly WMH, but the authors did not find associations with PVS. However, this analysis used a visual rating scale and considered PVS only in the basal ganglia, while the current computational measurements are in the centrum semiovale. This supports the hypothesis that the vascular drainage system differs in different brain regions, possibly due to regional variations in the vessel and PVS anatomy including fibrohyaline thickening, lipohyalinosis and cerebral amyloid angiopathy. In turn, these changes may affect vessel-brain fluid exchange and PVS morphology<sup>36-38</sup>.

The present findings add further support to the hypothesis that retinal fractal dimension is a possible indicator of the state of health of the brain vasculature and might have a significant associations with changes taking place in cerebral small vessels<sup>6</sup>. In line with our results, a previous study<sup>39</sup> reported that decreased retinal arterial fractal dimension was associated with cerebral microbleeds, suggesting that these retinal measures may correlate with the same manifestations of cerebral small vessel disease. It should however be kept in mind that the stability of the FD of the retinal and brain vasculature is under scrutiny<sup>40, 41</sup>.

Several clinical and population-based studies have shown associations between retinal vascular changes and markers of cerebral small vessel disease, as summarised in<sup>39</sup>. This paper provides an overview of findings on the application of retinal imaging to the study of dementia and stroke, suggesting that changes in retinal vascular measures may be an early manifestation of cerebral SVD<sup>42</sup>. A systematic review and meta-analysis of associations between retinal vascular morphologies and dementia<sup>8</sup>, found conflicting results for vessel calibre measurements, with the most consistent finding being a decreased fractal dimension in Alzheimer's disease. A decreased fractal dimension, indicating a sparser retinal vasculature, was also observed in lacunar versus non-lacunar stroke<sup>1</sup>.

Although smoking was only used as covariate in our study, we found a significant association of smoking with PVS size and width in the models predicting fractal dimension. This is consistent with previous studies indicating the deleterious effects of smoking on brain structure<sup>43, 44</sup> and increased total burden of SVD<sup>45</sup>. However this conflicts with findings from the Three-City Dijon MRI study that did not find associations between smoking and PVS visual scores<sup>46</sup>.



Eye laterality also deserves attention. Some studies choose to analyse the eye with the best image quality<sup>7</sup>; others randomly use either the left or right eye<sup>47</sup>. We decided to analyse the associations with both eyes separately and found asymmetric results. This supports some of the conclusions of the laterality study by Cameron et al.<sup>34</sup>. Future work could investigate the reasons for this, potentially looking at the carotid Doppler data<sup>48</sup>.

A limitation of our study is the cross-sectional design. Longitudinal studies examining retinal changes and progression of PVS and other SVD markers would be valuable to assess retinal arteriolar narrowing and vessel sparseness as predictors of increasing PVS enlargement and early manifestation of SVD. Such cohorts are not easily accessible. A second limitation is that it was possible to obtain valid quantitative measurements only in a subset of the sample (a large number of patients were excluded). Another limitation is the unknown effect of inaccuracies in the semi-automatic measurements of the retinal vasculature (for instance, CRAE and CRVE are subject to magnification effects and refractive error; FD is dependent on the vessel segmentation accuracy<sup>40</sup>, which in turn depends on image quality, presence of cataracts and floaters)<sup>49</sup>.

Strengths of our study include the use of multiple computational measurements of PVS burden, the careful blinding of retinal and brain image analysis, and the inclusion of relevant risk factors and vascular disease.

In conclusion, our study shows that elderly persons with retinal changes as narrower arterioles and reduced branching complexity are more likely to have higher PVS burden. This suggests that the retinal microvasculature can exhibit parallel signs of microvascular damage in the brain. Further studies are required to understand these mechanisms and their relation to dementia and stroke<sup>10</sup>.

## ACKNOWLEDGEMENTS

**Funding Sources:** The LBC1936 Study was funded by Age UK and the UK Medical Research Council (<http://www.disconnectedmind.ed.ac.uk/>) (including the Sidney De Haan Award for Vascular Dementia). Funds were also received from The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1), and the Biotechnology and Biological Sciences Research Council (BBSRC). The work was also funded by the EPSRC grant [LB EP/M005976/1], the Fondation Leducq Network for the Study of Perivascular Spaces in Small Vessel Disease [LB 16 CVD 05], the Row Fogo Charitable Trust [MVH Grant No. BROD.FID3668413], the European Union Horizon 2020 [PHC-03-15, project No 666881, 'SVDs@Target'], the UK Dementia Research Institute at the University of Edinburgh and the British Heart Foundation Centre for Research Excellence, Edinburgh.

## Author's Contributions:

Lucia Ballerini: development of the PVS segmentation tool and application to the cohort scans, checking the scans and editing, VAMPIRE software development, drafting and final approval the manuscript

Maria del C. Valdés Hernández and Susana Muñoz Maniega: image analysis and final approval of the manuscript

Sarah McGrory: VAMPIRE data collection, revision and final approval of the manuscript

Enrico Pellegrini, Tom MacGillivray, Emanuele Trucco: VAMPIRE software development, revision and final approval of the manuscript

Ross Henderson, Adele Taylor: data collection, revision and final approval of the manuscript

Ruggiero Lovreglio: software development, revision and final approval of the manuscript

Mark E. Bastin: MRI protocol design and quality assurance, revision and final approval of the manuscript

Ian J. Deary: LBC chief investigator, cohort recruitment, assessment, data analysis, revision and final approval of the manuscript.

Joanna M Wardlaw: study conception and design, data analysis and interpretation, revision and final approval of the manuscript

In addition, we thank the LBC1936 participants, nurses at the Edinburgh Clinical Research Facility, radiographers and other staff at the Edinburgh Imaging (<https://www.ed.ac.uk/clinical-sciences/edinburgh-imaging>): a SINAPSE collaboration Centre.

**Sponsor's Role:** The sponsors did not participate in the design, methods, subject recruitment, data collections, analysis or preparation of this manuscript

**Conflict of Interest Disclosure: none**

## REFERENCES

1. Doubal FN, Hokke PF and Wardlaw JM. Retinal microvascular abnormalities and stroke: a systematic review. *J Neurol Neurosurg Psychiatry*. 2009;80.
2. Lindley RI. Retinal Microvascular Signs: A Key to Understanding the Underlying Pathophysiology of Different Stroke Subtypes? *International Journal of Stroke*. 2008;3:297-305.
3. Arboix A. Retinal microvasculature in acute lacunar stroke. *The Lancet Neurology*. 2009;8:596-598.
4. Dumitrascu OM, Demaerschalk BM, Valencia Sanchez C, Almader-Douglas D, O'Carroll CB, Aguilar MI, Lyden PD and Kumar G. Retinal Microvascular Abnormalities as Surrogate Markers of Cerebrovascular Ischemic Disease: A Meta-Analysis. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association*. 2018;27:1960-1968.
5. Doubal FN, de Haan R Fau - MacGillivray TJ, MacGillivray Tj Fau - Cohn-Hokke PE, Cohn-Hokke Pe Fau - Dhillon B, Dhillon B Fau - Dennis MS, Dennis Ms Fau - Wardlaw JM and Wardlaw JM. Retinal arteriolar geometry is associated with cerebral white matter hyperintensities on magnetic resonance imaging. *Int J Stroke*. 2010;5.
6. McGrory S, Ballerini L, Doubal FN, Staals J, Allerhand M, Valdes-Hernandez MDC, Wang X,

- MacGillivray T, Doney ASF, Dhillon B, Starr JM, Bastin ME, Trucco E, Deary IJ and Wardlaw JM. Retinal microvasculature and cerebral small vessel disease in the Lothian Birth Cohort 1936 and Mild Stroke Study. *Sci Rep-Uk*. 2019;9:6320-6320.
7. Mutlu U, Adams HH, Hofman A, Lugt A, Klaver CC, Vernooij MW, Ikram MK and Ikram MA. Retinal Microvascular Calibers Are Associated With Enlarged Perivascular Spaces in the Brain. *Stroke*. 2016;47:1374-6.
  8. McGrory S, Cameron JR, Pellegrini E, Warren C, Doubal FN, Deary IJ, Dhillon B, Wardlaw JM, Trucco E and MacGillivray TJ. The application of retinal fundus camera imaging in dementia: A systematic review. *Alzheimer's & dementia (Amsterdam, Netherlands)*. 2016;6:91-107.
  9. Francis F, Ballerini L and Wardlaw JM. Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: A systematic review and meta-analysis. *International Journal of Stroke*. 2019;0:1747493019830321.
  10. Brown R, Benveniste H, Black SE, Charpak S, Dichgans M, Joutel A, Nedergaard M, Smith KJ, Zlokovic BV and Wardlaw JM. Understanding the role of the perivascular space in cerebral small vessel disease. *Cardiovascular Research*. 2018;cvy113-cvy113.
  11. Ramirez J, Berezuk C, McNeely AA, Gao F, McLaurin J and Black SE. Imaging the Perivascular Space as a Potential Biomarker of Neurovascular and Neurodegenerative Diseases. *Cellular and Molecular Neurobiology*. 2016;36:289-299.
  12. Potter GM, Doubal FN, Jackson CA, Chappell FM, Sudlow CL, Dennis MS and Wardlaw JM. Enlarged perivascular spaces and cerebral small vessel disease. *International Journal of Stroke*. 2015;10:376-381.
  13. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, DeCarli C, de Leeuw F-E, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge Rv, Pantoni L, Speck O, Stephan BCM, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M and nEuroimaging STfRVco. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *The Lancet Neurology*. 2013;12:822-838.
  14. Valdés-Hernández MdC, Piper RJ, Wang X, Deary IJ and Wardlaw JM. Towards the automatic computational assessment of enlarged perivascular spaces on brain magnetic resonance images: A systematic review. *Journal of Magnetic Resonance Imaging*. 2013;38:774-785.
  15. Debette S, Schilling S, Duperron M-G, Larsson SC and Markus HS. Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis. *Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury*. *JAMA neurology*. 2019;76:81-94.
  16. Potter GM, Chappell FM, Morris Z and Wardlaw JM. Cerebral Perivascular Spaces Visible on Magnetic Resonance Imaging: Development of a Qualitative Rating Scale and its Observer Reliability. *Cerebrovascular Diseases (Basel, Switzerland)*. 2015;39:224-231.
  17. Ramirez J, Berezuk C, McNeely AA, Scott CJ, Gao F and Black SE. Visible Virchow-Robin spaces on magnetic resonance imaging of Alzheimer's disease patients and normal elderly from the Sunnybrook Dementia Study. *J Alzheimers Dis*. 2015;43:415-24.
  18. Boespflug EL, Schwartz DL, Lahna D, Pollock J, Iliff JJ, Kaye JA, Rooney W and Silbert LC. MR Imaging-based Multimodal Autoidentification of Perivascular Spaces (mMAPS): Automated Morphologic Segmentation of Enlarged Perivascular Spaces at Clinical Field Strength. *Radiology*. 2018;286:632-642.
  19. Dubost F, Yilmaz P, Adams H, Bortsova G, Ikram MA, Niessen W, Vernooij M and de Bruijne M. Enlarged perivascular spaces in brain MRI: Automated quantification in four regions. *NeuroImage*. 2019;185:534-544.
  20. Ballerini L, Lovreglio R, Hernandez MDV, Ramirez J, MacIntosh BJ, Black SE and Wardlaw JM. Perivascular Spaces Segmentation in Brain MRI Using Optimal 3D Filtering. *Sci Rep-Uk*. 2018;8.
  21. Ballerini L, Lovreglio R, Hernández MdCV, Gonzalez-Castro V, Maniega SM, Pellegrini E,

- Bastin ME, Deary IJ and Wardlaw JM. Application of the Ordered Logit Model to Optimising Frangi Filter Parameters for Segmentation of Perivascular Spaces. *Procedia Computer Science*. 2016;90:61-67.
22. Deary IJ, Gow AJ, Taylor MD, Corley J, Brett C, Wilson V, Campbell H, Whalley LJ, Visscher PM, Porteous DJ and Starr JM. The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond. *BMC geriatrics*. 2007;7:28-28.
23. Wardlaw JM, Bastin ME, Valdes Hernandez M, Maniega SM, Royle NA, Morris Z, Clayden JD, Sandeman EM, Eadie E, Murray C, Starr JM and Deary IJ. Brain aging, cognition in youth and old age and vascular disease in the Lothian Birth Cohort 1936: rationale, design and methodology of the imaging protocol. *Int J Stroke*. 2011;6:547-59.
24. Taylor AM, Pattie A and Deary IJ. Cohort Profile Update: The Lothian Birth Cohorts of 1921 and 1936. *International Journal of Epidemiology*. 2018;47:1042-1042r.
25. Valdés-Hernández MdC, Ferguson KJ, Chappell FM and Wardlaw JM. New multispectral MRI data fusion technique for white matter lesion segmentation: method and comparison with thresholding in FLAIR images. *Eur Radiol*. 2010;20:1684-91.
26. Frangi AF, Niessen WJ, Vincken KL and Viergever MA. Multiscale vessel enhancement filtering. *Medical Image Computing and Computer-Assisted Intervention — MICCAI'98*. 1998:130-137.
27. Shapiro LG. Connected Component Labeling and Adjacency Graph Construction. In: T. Y. Kong and A. Rosenfeld, eds. *Machine Intelligence and Pattern Recognition*: North-Holland; 1996(19): 1-30.
28. Mookiah MRK, McGrory S, Hogg S, Price J, Forster R, MacGillivray TJ and Trucco E. Towards Standardization of Retinal Vascular Measurements: On the Effect of Image Centering. *Computational Pathology and Ophthalmic Medical Image Analysis*. 2018:294-302.
29. Trucco E, Giachetti A, Ballerini L, Relan D, Cavinato A, MacGillivray T, Lim J, Ong S and Xiong W. Morphometric measurements of the retinal vasculature in fundus images with vampire. *Biomedical Image Understanding*. 2015:91-111.
30. Trucco E, Ballerini L, Relan D, Giachetti A, MacGillivray T, Zutis K, Lupascu C, Tegolo D, Pellegrini E, Robertson G, Wilson PJ, Doney A and Dhillon B. Novel VAMPIRE algorithms for quantitative analysis of the retinal vasculature. *2013 ISSNIP Biosignals and Biorobotics Conference: Biosignals and Robotics for Better and Safer Living (BRC)*. 2013:1-4.
31. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, Klein BEK and Hubbard LD. Retinal Arteriolar Narrowing and Risk of Coronary Heart Disease in Men and Women The Atherosclerosis Risk in Communities Study. *JAMA*. 2002;287:1153-1159.
32. Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS, Sharrett AR, Davis MD and Cai J. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the atherosclerosis risk in communities study 1 | The authors have no proprietary interest in the equipment and techniques described in this article. *Ophthalmology*. 1999;106:2269-2280.
33. Huiqi L, Hsu W, Mong Li L and Tien Yin W. Automatic grading of retinal vessel caliber. *IEEE Transactions on Biomedical Engineering*. 2005;52:1352-1355.
34. Cameron JR, Megaw RD, Tatham AJ, McGrory S, MacGillivray TJ, Doubal FN, Wardlaw JM, Trucco E, Chandran S and Dhillon B. Lateral thinking – Interocular symmetry and asymmetry in neurovascular patterning, in health and disease. *Progress in Retinal and Eye Research*. 2017;59:131-157.
35. Keith J, Gao F-q, Noor R, Kiss A, Balasubramaniam G, Au K, Rogaeva E, Masellis M and Black SE. Collagenosis of the Deep Medullary Veins: An Underrecognized Pathologic Correlate of White Matter Hyperintensities and Periventricular Infarction? *Journal of Neuropathology & Experimental Neurology*. 2017;76:299-312.
36. Hurford R, Charidimou A, Fox Z, Cipolotti L, Jager R and Werring DJ. MRI-visible perivascular spaces: relationship to cognition and small vessel disease MRI markers in ischaemic stroke and TIA. *J Neurol Neurosurg Psychiatry*. 2014;85:522-5.
37. Zhang C, Chen Q, Wang Y, Zhao X, Wang C, Liu L, Pu Y, Zou X, Du W, Pan Y, Li Z, Jing J, Wang D, Luo Y, Wong KS and Wang Y. Risk factors of dilated Virchow-Robin Spaces are different in various brain regions. *PLoS ONE*. 2014;9.
38. Wardlaw JM, Smith C and Dichgans M. Mechanisms of sporadic cerebral small vessel disease:

- insights from neuroimaging. *The Lancet Neurology*. 2013;12:483-497.
39. Hilal S, Ong Y-T, Cheung CY, Tan CS, Venketasubramanian N, Niessen WJ, Vrooman H, Anuar AR, Chew M, Chen C, Wong TY and Ikram MK. Microvascular network alterations in retina of subjects with cerebral small vessel disease. *Neuroscience Letters*. 2014;577:95-100.
  40. Huang F, Zhang J, Bekkers EJ, Dashtbozorg B and ter Haar Romeny BM. Stability analysis of fractal dimension in retinal vasculature. 2015.
  41. Krohn S, Froeling M, Leemans A, Ostwald D, Villoslada P, Finke C and Esteban FJ. Evaluation of the 3D fractal dimension as a marker of structural brain complexity in multiple-acquisition MRI. *Human Brain Mapping*. 2019;40:3299-3320.
  42. Cheung CY-I, Ikram MK, Chen C and Wong TY. Imaging retina to study dementia and stroke. *Progress in Retinal and Eye Research*. 2017;57:89-107.
  43. Gons RAR, van Norden AGW, de Laat KF, van Oudheusden LJB, van Uden IWM, Zwiers MP, Norris DG and de Leeuw F-E. Cigarette smoking is associated with reduced microstructural integrity of cerebral white matter. *Brain*. 2011;134:2116-2124.
  44. Karama S, Ducharme S, Corley J, Chouinard-Decorte F, Starr JM, Wardlaw JM, Bastin ME and Deary IJ. Cigarette smoking and thinning of the brain's cortex. *Molecular Psychiatry*. 2015;20:778.
  45. Staals J, Booth T, Morris Z, Bastin ME, Gow AJ, Corley J, Redmond P, Starr JM, Deary IJ and Wardlaw JM. Total MRI load of cerebral small vessel disease and cognitive ability in older people. *Neurobiology of Aging*. 2015;36:2806-2811.
  46. Zhu YC, Tzourio C, Soumaré A, Mazoyer B, Dufouil C and Chabriat H. Severity of dilated perivascular spaces is associated with age, blood pressure, and MRI markers of small vessel disease: A population-based study. *Stroke*. 2010;41:2483-2490.
  47. Armstrong RA. Statistical guidelines for the analysis of data obtained from one or both eyes. *Ophthalmic and Physiological Optics*. 2013;33:7-14.
  48. De Silva DA, Liew G, Wong M-C, Chang H-M, Chen C, Wang J. J, Baker Michelle L, Hand Peter J, Rochtchina E, Liu Erica Y, Mitchell P, Lindley Richard I and Wong Tien Y. Retinal Vascular Caliber and Extracranial Carotid Disease in Patients With Acute Ischemic Stroke. *Stroke*. 2009;40:3695-3699.
  49. McGrory S, Taylor AM, Pellegrini E, Ballerini L, Kirin M, Doubal FN, Wardlaw JM, Doney ASF, Dhillon B, Starr JM, Trucco E, Deary IJ and MacGillivray TJ. Towards Standardization of Quantitative Retinal Vascular Parameters: Comparison of SIVA and VAMPIRE Measurements in the Lothian Birth Cohort 1936. *Translational vision science & technology*. 2018;7:12-12.



**Table 1** Brain imaging volumetric measures, vascular risk factors and retinal vascular measurements considered in the analyses and comparing those included vs excluded from the analysis.

| <b>Variable Types</b>                            | Included ( <i>n</i> = 381) | Excluded ( <i>n</i> = 485) | p-value |
|--|----------------------------|----------------------------|---------|
| Age (years) [mean (SD)]                          | 72.47 (0.69)               | 72.60 (0.71)               | 0.007   |
| Gender [% ( <i>n</i> )]                          |                            |                            |         |
| Male   | 51.18 (195)                | 52.16 (253)                | 0.83    |
| Female   | 48.82 (186)                | 47.84 (232)                |         |
| <b>Vascular Risk Factors [% (<i>n</i>)]</b>      |                            |                            |         |
| Hypertension                                     | 43.31 (165)                | 53.61 (260)                | 0.003   |
| Diabetes   | 8.92 (34)                  | 12.58 (61)                 | 0.11    |
| Cholesterol                                      | 34.91 (133)                | 45.98 (223)                | 0.001   |
| CVD  | 26.25 (100)                | 30.93 (150)                | 0.15    |
| Smoking  | 7.61 (29)                  | 9.07 (44)                  | 0.40    |
| Stroke   | 17.32 (66)                 | 6.36 (31)                  | N.A.    |
| <b>Brain Measurements [mean (SD)]</b>            |                            |                            |         |
| WMH (%ICV)                                       | 0.81 (0.89)                |                            |         |
| PVS count  | 254.4 (90.13)              |                            |         |
| PVS total volume                                 | 3197 (1404.06)             |                            |         |
| PVS mean length                                  | 3.91 (0.53)                |                            |         |
| PVS mean width                                   | 1.99 (0.34)                |                            |         |
| PVS mean size                                    | 13.49 (4.70)               |                            |         |
| <b>Retinal Vascular Measurements [mean (SD)]</b> |                            |                            |         |
| Left CRAE  | 30.95 (2.78)               |                            |         |
| Left CRVE  | 42.1 (3.99)                |                            |         |
| Left AVR   | 0.74 (0.08)                |                            |         |
| Left FDa   | 1.61 (0.06)                |                            |         |
| Left FDv   | 1.59 (0.05)                |                            |         |
| Right CRAE                                       | 31.27 (2.46)               |                            |         |
| Right CRVE                                       | 41.93 (3.89)               |                            |         |
| Right AVR  | 0.75 (0.07)                |                            |         |
| Right FDa  | 1.57 (0.75)                |                            |         |
| Right FDv  | 1.56 (0.06)                |                            |         |

*Note:* *n*: valid sample size, CVD: history of cardiovascular disease, WMH: white matter hyperintensities, PVS: perivascular spaces, CRAE: Central Retinal Arterial Equivalent, CRAE: Central Retinal Venular Equivalent, AVR: Arteriole to Venule Ratio, FD: Fractal Dimension, a: artery, v: vein,

**Table 2.** Bivariate pairwise cross-correlations between the brain and retinal imaging variables evaluated. Spearman ( $\rho$ ) values. Left eye values are given in the lower left part of the Table (light red) and Right values are given in the upper right part (light green). The significance level is indicated as follows: \* $p < 0.05$ , \*\* $p < 0.01$  (Bold type). Results underlined survived FDR correction.

|                  | PVS total volume       | PVS count              | PVS length            | PVS width              | PVS size               | Right CRAE            | Right CRVE             | Right AVR             | Right FDa             | Right FDv             |
|------------------|------------------------|------------------------|-----------------------|------------------------|------------------------|-----------------------|------------------------|-----------------------|-----------------------|-----------------------|
| PVS total volume | 1                      | <b><u>0.924**</u></b>  | <b><u>0.868**</u></b> | <b><u>0.875**</u></b>  | <b><u>0.852**</u></b>  | <u>-0.123*</u>        | -0.084                 | -0.021                | -0.093                | -0.047                |
| PVS count        | <b><u>0.924**</u></b>  | 1                      | <b><u>0.710**</u></b> | <b><u>0.686**</u></b>  | <b><u>0.627**</u></b>  | -0.104*               | -0.102*                | 0.016                 | -0.030                | -0.028                |
| PVS length       | <b><u>0.868**</u></b>  | <b><u>0.710**</u></b>  | 1                     | <b><u>0.939**</u></b>  | <b><u>0.922**</u></b>  | <u>-0.129*</u>        | -0.043                 | -0.065                | <u>-0.118*</u>        | -0.040                |
| PVS width        | <b><u>0.875**</u></b>  | <b><u>0.686**</u></b>  | <b><u>0.939**</u></b> | 1                      | <b><u>0.971**</u></b>  | <u>-0.128*</u>        | -0.053                 | -0.058                | <u>-0.129*</u>        | -0.049                |
| PVS size         | <b><u>0.852**</u></b>  | <b><u>0.627**</u></b>  | <b><u>0.922**</u></b> | <b><u>0.971**</u></b>  | 1                      | <u>-0.127*</u>        | -0.065                 | -0.051                | <u>-0.145*</u>        | -0.053                |
| Left CRAE        | <b><u>-0.177**</u></b> | <b><u>-0.191**</u></b> | <u>-0.123*</u>        | <u>-0.114*</u>         | <u>-0.121*</u>         | <b><u>0.406**</u></b> | <b><u>0.154**</u></b>  | <b><u>0.153**</u></b> | <u>0.123*</u>         | 0.018                 |
| Left CRVE        | -0.035                 | -0.047                 | -0.026                | -0.038                 | -0.037                 | <b><u>0.236**</u></b> | <b><u>0.331**</u></b>  | <u>-0.126*</u>        | 0.110*                | 0.112*                |
| Left AVR         | <u>-0.126*</u>         | <b><u>-0.133**</u></b> | -0.077                | -0.059                 | -0.068                 | <b><u>0.139**</u></b> | <b><u>-0.159**</u></b> | <b><u>0.256**</u></b> | 0.015                 | -0.093                |
| Left FDa         | <b><u>-0.134**</u></b> | -0.088                 | <u>-0.120*</u>        | <b><u>-0.136**</u></b> | <b><u>-0.150**</u></b> | <b><u>0.176**</u></b> | <b><u>0.242**</u></b>  | -0.087                | <b><u>0.307**</u></b> | <b><u>0.285**</u></b> |
| Left FDv         | <u>-0.119*</u>         | -0.093                 | -0.109*               | <u>-0.127*</u>         | <b><u>-0.140**</u></b> | 0.034                 | <b><u>0.163**</u></b>  | <u>-0.112*</u>        | <u>0.127*</u>         | <b><u>0.273**</u></b> |

*Note:* PVS: perivascular spaces, CRAE: Central Retinal Arterial Equivalent, CRAE: Central Retinal Venular Equivalent, AVR: Arteriole to Venule Ratio, FD: Fractal Dimension, a: artery, v: vein.




**Table 3.** Associations of brain and retinal imaging variables adjusted for age, gender and vascular risk factors. Bold type indicates  $p < 0.05$ . Results underlined survived FDR correction.

| Model no. | Outcome name            | Predictors (in addition to age and biological sex) |                         |                        |                      |                     |                       |
|-----------|-------------------------|--|-------------------------|------------------------|----------------------|---------------------|-----------------------|
|           |                         | Name   | Unstandardised values   |                        | Standardised values  |                     | p-value               |
|           |                         |  | B                       | SE                     | Beta                 | SE                  |                       |
| 1         | <b>PVS total volume</b> | Hypertension                                       | 1.59e-04                | 1.30e-04               | 0.066                | 0.055               | 0.22                  |
|           |                         | Diabetes   | 1.98e-04                | 2.17e-04               | 0.052                | 0.057               | 0.36                  |
|           |                         | Hypercholesterolaemia                              | -1.58e-04               | 1.34e-04               | -0.065               | 0.055               | 0.24                  |
|           |                         | History of CVD                                     | 4.53e-05                | 1.41e-04               | 0.017                | 0.053               | 0.75                  |
|           |                         | <b>Smoking</b>                                     | <b>5.73e-04</b>         | <b>2.28e-04</b>        | <b>0.127</b>         | <b>0.051</b>        | <b>0.012</b>          |
|           |                         | Previous stroke                                    | 2.95e-04                | 1.64e-04               | 0.093                | 0.052               | 0.07                  |
|           |                         | <b>Left CRAE</b>                                   | <b><u>-7.33e-05</u></b> | <b><u>2.21e-05</u></b> | <b><u>-0.170</u></b> | <b><u>0.051</u></b> | <b><u>0.00101</u></b> |
| 2         | <b>PVS total volume</b> | Hypertension                                       | 1.43e-04                | 1.31e-04               | 0.060                | 0.054               | 0.27                  |
|           |                         | Diabetes   | 2.18e-04                | 2.18e-04               | 0.057                | 0.057               | 0.32                  |
|           |                         | Hypercholesterolaemia                              | -1.57e-04               | 1.35e-04               | -0.065               | 0.055               | 0.24                  |
|           |                         | History of CVD                                     | 3.25e-05                | 1.41e-04               | 0.001                | 0.053               | 0.98                  |
|           |                         | <b>Smoking</b>                                     | <b>5.27e-04</b>         | <b>2.29e-04</b>        | <b>0.117</b>         | <b>0.051</b>        | <b>0.022</b>          |
|           |                         | <b>Previous stroke</b>                             | <b>3.48e-04</b>         | <b>1.65e-04</b>        | <b>0.110</b>         | <b>0.052</b>        | <b>0.035</b>          |
|           |                         | <b>Left FDa</b>                                    | <b>-2.89e-03</b>        | <b>1.07e-03</b>        | <b>-0.137</b>        | <b>0.051</b>        | <b>0.00704</b>        |
| 3         | <b>PVS total volume</b> | Hypertension                                       | 1.77e-04                | 1.31e-04               | 0.074                | 0.055               | 0.18                  |
|           |                         | Diabetes   | 2.12e-04                | 2.18e-04               | 0.055                | 0.057               | 0.33                  |
|           |                         | Hypercholesterolaemia                              | -1.96e-04               | 1.36e-04               | -0.081               | 0.057               | 0.15                  |
|           |                         | History of CVD                                     | -2.35e-07               | 1.41e-04               | -0.009               | 0.053               | 0.86                  |
|           |                         | <b>Smoking</b>                                     | <b>5.53e-04</b>         | <b>2.29e-04</b>        | <b>0.123</b>         | <b>0.051</b>        | <b>0.016</b>          |
|           |                         | <b>Previous stroke</b>                             | <b>3.62e-04</b>         | <b>1.65e-04</b>        | <b>0.115</b>         | <b>0.052</b>        | <b>0.029</b>          |
|           |                         | <b>Left FDv</b>                                    | <b>-3.32e-03</b>        | <b>1.22e-03</b>        | <b>-0.139</b>        | <b>0.051</b>        | <b>0.00678</b>        |
| 4         | <b>PVS count</b>        | Hypertension                                       | 8.11                    | 9.86                   | 0.045                | 0.055               | 0.41                  |
|           |                         | Diabetes   | 16.08                   | 16.48                  | 0.056                | 0.057               | 0.33                  |
|           |                         | Hypercholesterolaemia                              | -5.56                   | 10.16                  | -0.030               | 0.055               | 0.59                  |
|           |                         | History of CVD                                     | 0.43                    | 10.71                  | 0.002                | 0.054               | 0.97                  |
|           |                         | Smoking  | 18.41                   | 17.29                  | 0.054                | 0.051               | 0.29                  |
|           |                         | Previous stroke                                    | 3.59                    | 12.43                  | 0.015                | 0.052               | 0.77                  |
|           |                         | <b>Left CRAE</b>                                   | <b><u>-5.95</u></b>     | <b><u>1.68</u></b>     | <b><u>-0.184</u></b> | <b><u>0.052</u></b> | <b><u>0.00043</u></b> |
| 5         | PVS count               | Hypertension                                       | 5.44e+00                | 9.98e+00               | 0.030                | 0.055               | 0.59                  |
|           |                         | Diabetes   | 1.71e+01                | 1.67e+01               | 0.059                | 0.058               | 0.31                  |
|           |                         | Hypercholesterolaemia                              | -4.16e+00               | 1.03e+01               | -0.023               | 0.056               | 0.69                  |
|           |                         | History of CVD                                     | -7.74e-01               | 1.09e+01               | -0.004               | 0.051               | 0.94                  |
|           |                         | Smoking  | 1.74e+01                | 1.75e+01               | 0.051                | 0.052               | 0.32                  |
|           |                         | Previous stroke                                    | 5.61e+00                | 1.26e+01               | 0.024                | 0.053               | 0.66                  |
|           |                         | Left AVR   | -1.26e+02               | 6.20e+01               | -0.105               | 0.052               | 0.0433                |


|   |           |                        |                         |                        |                      |                     |                       |
|---|-----------|------------------------|-------------------------|------------------------|----------------------|---------------------|-----------------------|
| 6 | PVS width | Hypertension           | 5.54e-02                | 3.71e-02               | 0.081                | 0.054               | 0.14                  |
|   |           | Diabetes               | 3.69e-02                | 6.20e-02               | 0.034                | 0.057               | 0.55                  |
|   |           | Hypercholesterolaemia  | -5.99e-02               | 3.82e-02               | -0.086               | 0.055               | 0.11                  |
|   |           | History of CVD         | 6.84e-03                | 4.01e-02               | 0.009                | 0.053               | 0.86                  |
|   |           | <b>Smoking</b>         | <b><u>1.80e-01</u></b>  | <b><u>6.51e-02</u></b> | <b><u>0.139</u></b>  | <b><u>0.051</u></b> | <b><u>0.00612</u></b> |
|   |           | <b>Previous stroke</b> | <b><u>1.10e-01</u></b>  | <b><u>4.67e-02</u></b> | <b><u>0.122</u></b>  | <b><u>0.052</u></b> | <b><u>0.019</u></b>   |
|   |           | <b>Left FDa</b>        | <b><u>-8.66e-01</u></b> | <b><u>3.03e-01</u></b> | <b><u>-0.144</u></b> | <b><u>0.050</u></b> | <b><u>0.00444</u></b> |
| 7 | PVS width | Hypertension           | 6.63e-02                | 3.71e-02               | 0.097                | 0.054               | 0.08                  |
|   |           | Diabetes               | 3.53e-02                | 6.19e-02               | 0.032                | 0.057               | 0.57                  |
|   |           | Hypercholesterolaemia  | -7.26e-02               | 3.84e-02               | -0.104               | 0.055               | 0.06                  |
|   |           | History of CVD         | -1.65e-03               | 4.00e-02               | -0.002               | 0.053               | 0.97                  |
|   |           | <b>Smoking</b>         | <b><u>1.87e-01</u></b>  | <b><u>6.49e-02</u></b> | <b><u>0.145</u></b>  | <b><u>0.050</u></b> | <b><u>0.00415</u></b> |
|   |           | <b>Previous stroke</b> | <b><u>1.15e-01</u></b>  | <b><u>4.67e-02</u></b> | <b><u>0.128</u></b>  | <b><u>0.052</u></b> | <b><u>0.014</u></b>   |
|   |           | <b>Left FDv</b>        | <b><u>-1.08e+00</u></b> | <b><u>3.46e-01</u></b> | <b><u>-0.158</u></b> | <b><u>0.051</u></b> | <b><u>0.00197</u></b> |
| 8 | PVS size  | Hypertension           | 5.73e-01                | 5.08e-01               | 0.061                | 0.054               | 0.26                  |
|   |           | Diabetes               | 1.18e-01                | 8.50e-01               | 0.008                | 0.057               | 0.89                  |
|   |           | Hypercholesterolaemia  | -6.18e-01               | 5.24e-01               | -0.065               | 0.055               | 0.24                  |
|   |           | History of CVD         | 7.81e-01                | 5.49e-01               | 0.008                | 0.053               | 0.89                  |
|   |           | <b>Smoking</b>         | <b><u>2.73e+00</u></b>  | <b><u>8.93e-01</u></b> | <b><u>0.154</u></b>  | <b><u>0.050</u></b> | <b><u>0.00243</u></b> |
|   |           | <b>Previous stroke</b> | <b><u>1.50e+00</u></b>  | <b><u>6.41e-01</u></b> | <b><u>0.121</u></b>  | <b><u>0.052</u></b> | <b><u>0.019</u></b>   |
|   |           | <b>Left FDa</b>        | <b><u>-1.30e+01</u></b> | <b><u>4.15e+00</u></b> | <b><u>-0.157</u></b> | <b><u>0.050</u></b> | <b><u>0.00194</u></b> |
| 9 | PVS size  | Hypertension           | 7.27e-01                | 5.10e-01               | 0.077                | 0.054               | 0.16                  |
|   |           | Diabetes               | 9.14e-02                | 8.50e-01               | 0.006                | 0.056               | 0.91                  |
|   |           | Hypercholesterolaemia  | -7.96e-01               | 5.27e-01               | -0.083               | 0.055               | 0.13                  |
|   |           | History of CVD         | -4.35e-02               | 5.50e-01               | -0.004               | 0.053               | 0.94                  |
|   |           | <b>Smoking</b>         | <b><u>2.84e+00</u></b>  | <b><u>8.91e-01</u></b> | <b><u>0.160</u></b>  | <b><u>0.050</u></b> | <b><u>0.00155</u></b> |
|   |           | <b>Previous stroke</b> | <b><u>1.57e+00</u></b>  | <b><u>6.42e-01</u></b> | <b><u>0.127</u></b>  | <b><u>0.052</u></b> | <b><u>0.015</u></b>   |
|   |           | <b>Left FDv</b>        | <b><u>-1.52e+01</u></b> | <b><u>4.75e+00</u></b> | <b><u>-0.162</u></b> | <b><u>0.051</u></b> | <b><u>0.00149</u></b> |

Note: PVS: perivascular spaces, CRAE: Central Retinal Arterial Equivalent, CRAE: Central Retinal Venular Equivalent, AVR: Arteriole to Venule Ratio, FD: Fractal Dimension, a: artery, v: vein, CVD: history of cardiovascular disease.


## FIGURES




**Figure 1** a) Axial T2-weighted slice showing in yellow the results of the PVS segmentation in a typical brain. B) Schematic illustration of the individual PVS metrics




**Figure 2** Retinal fundus image. Solid lines (red for arterioles and dark blue for venules) represent the vessels detected automatically and measured by VAMPIRE. Dotted lines represent the vessels widths



**Figure 3** Flow chart of the analytic sample for the current study



**Figure 4** Distribution of PVS score, total volume and count in the centrum semiovale



**Figure 5** Scatter plots of left CRAE and AVR vs count and total volume of PVS in the centrum semiovale